Aaron Wealth Advisors LLC Reduces Holdings in Kura Oncology, Inc. (NASDAQ:KURA)

Aaron Wealth Advisors LLC reduced its position in Kura Oncology, Inc. (NASDAQ:KURA) by 3.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 65,685 shares of the company’s stock after selling 2,306 shares during the period. Aaron Wealth Advisors LLC owned approximately 0.08% of Kura Oncology worth $572,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of KURA. Harbor Capital Advisors Inc. boosted its holdings in Kura Oncology by 4.4% in the fourth quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company’s stock valued at $430,000 after purchasing an additional 2,076 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Kura Oncology by 0.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 409,241 shares of the company’s stock valued at $7,997,000 after purchasing an additional 3,092 shares during the period. Armistice Capital LLC grew its position in shares of Kura Oncology by 14.7% during the second quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock worth $48,386,000 after acquiring an additional 302,000 shares during the last quarter. HighVista Strategies LLC acquired a new stake in shares of Kura Oncology in the second quarter valued at approximately $345,000. Finally, Alethea Capital Management LLC increased its position in Kura Oncology by 2.4% in the 2nd quarter. Alethea Capital Management LLC now owns 265,906 shares of the company’s stock valued at $5,475,000 after acquiring an additional 6,300 shares during the period.

Kura Oncology Stock Up 1.1 %

Shares of KURA stock opened at $7.26 on Monday. The stock’s 50 day simple moving average is $10.51 and its 200 day simple moving average is $16.33. Kura Oncology, Inc. has a twelve month low of $6.98 and a twelve month high of $24.17. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The company has a market capitalization of $564.54 million, a price-to-earnings ratio of -3.08 and a beta of 0.81.

Analysts Set New Price Targets

KURA has been the topic of a number of research reports. StockNews.com downgraded Kura Oncology from a “hold” rating to a “sell” rating in a research note on Wednesday, November 20th. Jefferies Financial Group decreased their price objective on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating for the company in a research note on Thursday, November 21st. HC Wainwright upped their target price on Kura Oncology from $32.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, November 21st. TD Cowen restated a “buy” rating on shares of Kura Oncology in a report on Thursday, November 21st. Finally, JMP Securities reiterated a “market outperform” rating and set a $32.00 price objective on shares of Kura Oncology in a report on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.38.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.